inotuzumab
pfizer,ucb pharmaceuticals
['inotuzumab ozogamicin', 'inotuzumab']
congress| #asco23 maureen o'brien, discusses aall1732 phase 3 trial investigating safety outcomes in newly diagnosed patients treated with inotuzumab ozogamicin for high-risk b-all. further modifications to mitigate toxicity are suggested for future studies #allsm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm